Bayer confronts €5 bn glyphosate legal burden as it launches AI drug‑discovery partnership

German pharmaceutical group Bayer disclosed that it expects to allocate about €5 billion to glyphosate‑related legal settlements and court costs by 2026, a sum that could keep free cash flow negative despite operational progress. The company recently received FDA approval for the low‑dose MRI contrast agent AMBELVIST® and opened an innovation centre in Shandong, China, to boost its Consumer Health research.

In parallel, Bayer announced a collaboration with U.S. biotech firm Iambic Therapeutics to use an artificial‑intelligence platform for target identification and accelerated molecule design. The partnership includes an upfront payment and milestone‑linked royalties, reflecting a broader industry shift toward integrating AI into drug‑discovery pipelines.